

Amar U Kishan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4711266/amar-u-kishan-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150
papers

2,226
citations

21
h-index

43
g-index

180
ext. papers

3,389
ext. citations

6
avg, IF

5.08
L-index

#	Paper	IF	Citations
150	Developing a Mobile Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Administration System to Capture Postradiation Toxicity in Oncology: Usability and Feasibility Study.. <i>JMIR Formative Research</i> , 2022 , 6, e27775	2.5	0
149	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.. <i>Prostate Cancer and Prostatic Diseases</i> , 2022 ,	6.2	1
148	Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer: A Patient-Level Data Analysis of 3 Cohorts.. <i>JAMA Oncology</i> , 2022 ,	13.4	2
147	Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.. <i>Radiotherapy and Oncology</i> , 2022 , 167, 226-232	5.3	2
146	Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.. <i>Lancet Oncology</i> , The , 2022 ,	21.7	8
145	Pan-cancer analysis of prognostic metastatic phenotypes. <i>International Journal of Cancer</i> , 2022 , 150, 132-141	7.5	0
144	Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel.. <i>Frontiers in Oncology</i> , 2022 , 12, 853246	5.3	0
143	Prostate-Centric Versus Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer with Simultaneous Integrated Boost: A Dosimetric Comparison.. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100944	3.3	
142	Dual X-ray Absorptiometry Screening for Men Receiving Androgen Deprivation Therapy-Hiding in Plain (Film) Sight.. <i>JAMA Network Open</i> , 2022 , 5, e225439	10.4	
141	A Prospective Study of High Dose-Rate Brachytherapy or Stereotactic Body Radiotherapy of Intra-Prostatic Recurrence: Toxicity and Long Term Clinical Outcome.. <i>Frontiers in Oncology</i> , 2022 , 12, 861127	5.3	1
140	High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.. <i>European Urology</i> , 2022 ,	10.2	1
139	Genomic biomarkers to guide precision radiotherapy in prostate cancer. <i>Prostate</i> , 2022 , 82,	4.2	0
138	A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>European Urology</i> , 2021 , 80, 280-292	10.2	42
137	Dosimetric impact of interfraction prostate and seminal vesicle volume changes and rotation: A post-hoc analysis of a phase III randomized trial of MRI-guided versus CT-guided stereotactic body radiotherapy.. <i>Radiotherapy and Oncology</i> , 2021 , 167, 203-210	5.3	4
136	Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.. <i>JAMA Network Open</i> , 2021 , 4, e2138550	10.4	3
135	Bladder surface dose modeling in prostate cancer radiotherapy: An analysis of motion-induced variations and the cumulative dose across the treatment. <i>Medical Physics</i> , 2021 , 48, 8024	4.4	0
134	Simulated consult and treatment exercise improves radiation oncology trainee confidence and knowledge. <i>Journal of Education and Health Promotion</i> , 2021 , 10, 218	1.4	

133	Time-Driven Activity-Based Costing of CT-Guided vs MR-Guided Prostate SBRT 2021 , 10, 33-40		
132	Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. <i>Radiotherapy and Oncology</i> , 2021 , 166, 1-7	5.3	3
131	Magnetic resonance linear accelerator technology and adaptive radiation therapy: An overview for clinicians. <i>Ca-A Cancer Journal for Clinicians</i> , 2021 , 72, 34	220.7	2
130	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology, The</i> , 2021 , 22, 402-410	21.7	21
129	Caught Between a Rock and a Hard Place. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 846-847	4	
128	Update from PSMA-SRT Trial NCT03582774: A Randomized Phase 3 Imaging Trial of Prostate-specific Membrane Antigen Positron Emission Tomography for Salvage Radiation Therapy for Prostate Cancer Recurrence Powered for Clinical Outcome. <i>European Urology Focus</i> , 2021 , 7, 238-240	5.1	12
127	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1279-1285	4	6
126	Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol. <i>BMC Cancer</i> , 2021 , 21, 512	4.8	2
125	Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial. <i>BMC Cancer</i> , 2021 , 21, 538	4.8	8
124	Use and Impact of Positron Emission Tomography/Computed Tomography Prior to Salvage Radiation Therapy in Men with Biochemical Recurrence After Radical Prostatectomy: A Scoping Review. <i>European Urology Oncology</i> , 2021 , 4, 339-355	6.7	8
123	Interfractional Geometric Variations and Dosimetric Benefits of Stereotactic MRI Guided Online Adaptive Radiotherapy (SMART) of Prostate Bed after Radical Prostatectomy: Post-Hoc Analysis of a Phase II Trial. <i>Cancers</i> , 2021 , 13,	6.6	1
122	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021 , 79, 717-721	10.2	4
121	Ablative Radiotherapy for Liver Tumors Using Stereotactic MRI-Guidance: A Prospective Phase I Trial. <i>Radiotherapy and Oncology</i> , 2021 ,	5.3	4
120	The intraprostatic immune environment after stereotactic body radiotherapy is dominated by myeloid cells. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 135-139	6.2	3
119	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021 , 154, 207-213	5.3	6
118	Adaptive Radiation Therapy (ART) Strategies and Technical Considerations: A State of the ART Review From NRG Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1054-1075	1075	19
117	Prostate-specific Membrane Antigen Positron Emission Tomography-guided Radiotherapy. <i>European Urology Focus</i> , 2021 , 7, 250-253	5.1	5
116	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021 , 79, 374-383	10.2	28

115	Stereotactic body radiation therapy use for high risk prostate cancer in the United States. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 578-581	6.2	0
114	Executive Summary of the American Radium Society Appropriate Use Criteria for Radiation Treatment of Node-Negative Muscle Invasive Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 953-963	4	5
113	False positive PSMA PET for tumor remnants in the irradiated prostate and other interpretation pitfalls in a prospective multi-center trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 501-508	8.8	12
112	Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. <i>European Urology Oncology</i> , 2021 , 4, 327-330	6.7	2
111	Multi-task edge-recalibrated network for male pelvic multi-organ segmentation on CT images. <i>Physics in Medicine and Biology</i> , 2021 , 66, 035001	3.8	1
110	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021 , 80, 632-640	10.2	14
109	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. <i>European Urology Oncology</i> , 2021 , 5, 100-100	6.7	8
108	Comparison of Multimodal Therapies and Outcomes Among Patients With High-Risk Prostate Cancer With Adverse Clinicopathologic Features. <i>JAMA Network Open</i> , 2021 , 4, e2115312	10.4	1
107	Clinical assessment of geometric distortion for a 0.35T MR-guided radiotherapy system. <i>Journal of Applied Clinical Medical Physics</i> , 2021 , 22, 303-309	2.3	1
106	Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 110, 731-737	4	7
105	Reply to Sungeun Kim, Jae Il Shin, and Jonathan Evan Shoag. Letter to the Editor re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2020.11.010 . <i>European Urology</i> , 2021 , 80, e15-e16	10.2	
104	Radiation therapy dose and androgen deprivation therapy in localized prostate cancer: a meta-regression of 5-year outcomes in phase III randomized controlled trials. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 ,	6.2	1
103	Salvage therapy for prostate cancer after radical prostatectomy. <i>Nature Reviews Urology</i> , 2021 , 18, 643-668	9.9	6
102	Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer. <i>European Urology</i> , 2021 , 80, 142-146	10.2	3
101	Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. <i>Advances in Radiation Oncology</i> , 2021 , 6, 100759	3.3	
100	A Practical Guide for Navigating the Design, Build, and Clinical Integration of Electronic Patient-Reported Outcomes in the Radiation Oncology Department. <i>Practical Radiation Oncology</i> , 2021 , 11, e376-e383	2.8	3
99	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.. <i>JAMA Network Open</i> , 2021 , 4, e2139769	10.4	2
98	MR-Guided Radiotherapy for Prostate Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 616291	5.3	21

97	Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2020 , 3, e2017144	10.4	2
96	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3024-3031	2.2	11
95	Clinical Assessment of Prostate Displacement and Planning Target Volume Margins for Stereotactic Body Radiotherapy of Prostate Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 539	5.3	13
94	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020 , 78, 327-332	10.2	9
93	Dosimetric predictors of patient-reported toxicity after prostate stereotactic body radiotherapy: Analysis of full range of the dose-volume histogram using ensemble machine learning. <i>Radiotherapy and Oncology</i> , 2020 , 148, 181-188	5.3	2
92	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 917-926	4	7
91	Stereotactic Body Radiotherapy for Prostate Cancer. <i>American Journal of Men's Health</i> , 2020 , 14, 1557988320907241	8.3	2
90	Development and Validation of a Comprehensive Multivariate Dosimetric Model for Predicting Late Genitourinary Toxicity Following Prostate Cancer Stereotactic Body Radiotherapy. <i>Frontiers in Oncology</i> , 2020 , 10, 786	5.3	1
89	Phase 1 Trial of Stereotactic Body Radiation Therapy Neoadjuvant to Radical Prostatectomy for Patients With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 930-935	4	4
88	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020 , 6, 735-743	13.4	23
87	Salvage therapy at biochemical recurrence of prostate cancer. <i>Nature Reviews Urology</i> , 2020 , 17, 195-196	5.5	1
86	A novel anthropomorphic multimodality phantom for MRI-based radiotherapy quality assurance testing. <i>Medical Physics</i> , 2020 , 47, 1443-1451	4.4	7
85	Impact of Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 1153-1160	8.9	37
84	Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. <i>Radiotherapy and Oncology</i> , 2020 , 148, 235-242	5.3	17
83	Targeted radiation: Specificity and deescalation 2020 , 165-195		
82	Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer. <i>Translational Andrology and Urology</i> , 2020 , 9, 2326-2328	2.3	
81	Pelvic nodal radiotherapy in Gleason grade group 5 prostate cancer. <i>Translational Andrology and Urology</i> , 2020 , 9, 2326-2328	2.3	
80	Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. <i>European Urology</i> , 2020 , 77, 201-208	10.2	21

79	Quantification of fiducial marker visibility for MRI-only prostate radiotherapy simulation. <i>Physics in Medicine and Biology</i> , 2020 , 65, 035015	3.8	2
78	A generative adversarial network-based (GAN-based) architecture for automatic fiducial marker detection in prostate MRI-only radiotherapy simulation images. <i>Medical Physics</i> , 2020 , 47, 6405-6413	4.4	1
77	PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics. <i>Clinical Nuclear Medicine</i> , 2020 , 45, e309-e310	1.7	1
76	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020 , 151, 26-32	5.3	11
75	Local failure in high grade prostate cancer: the importance of local and systemic therapy. <i>Translational Andrology and Urology</i> , 2020 , 9, 2315-2317	2.3	
74	Impact of Health-related Quality of Life and Prediagnosis Risk of Major Depressive Disorder on Treatment Choice in Low- and Intermediate-Risk Prostate Cancer. <i>European Urology Open Science</i> , 2020 , 21, 69-76	0.9	0
73	The Impact of F-DCFPyL PET-CT Imaging on Initial Staging, Radiation, and Systemic Therapy Treatment Recommendations for Veterans With Aggressive Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020 , 5, 1364-1369	3.3	4
72	Analysis of Geometric Performance and Dosimetric Impact of Using Automatic Contour Segmentation for Radiotherapy Planning. <i>Frontiers in Oncology</i> , 2020 , 10, 1762	5.3	7
71	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020 , 5, 26-32	3.3	10
70	Practical Safety Considerations for Integration of Magnetic Resonance Imaging in Radiation Therapy. <i>Practical Radiation Oncology</i> , 2020 , 10, 443-453	2.8	5
69	Clinical Development and Evaluation of Megavoltage Topogram for Fast Patient Alignment on Helical Tomotherapy. <i>Advances in Radiation Oncology</i> , 2020 , 5, 1334-1341	3.3	
68	Ablative Radiotherapy in Prostate Cancer: Stereotactic Body Radiotherapy and High Dose Rate Brachytherapy. <i>Cancers</i> , 2020 , 12,	6.6	4
67	Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. <i>European Urology</i> , 2020 , 77, 3-10	10.2	9
66	Gantry-Mounted Linear Accelerator-Based Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2020 , 5, 404-411	3.3	5
65	Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy. <i>Radiotherapy and Oncology</i> , 2020 , 148, 44-50	5.3	8
64	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020 , 5, 659-665	3.3	100
63	Association between Long-Term Second Malignancy Risk and Radiation: A Comprehensive Analysis of the Entire Surveillance, Epidemiology, and End Results Database (1973-2014). <i>Advances in Radiation Oncology</i> , 2019 , 4, 738-747	3.3	1
62	MicroRNA-based Biomarkers predicting Long-Term Toxicity to Prostate SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, S39-S40	4	2

61	Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 149-154	4	4
60	Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 628-636	4	12
59	Re: Sebastian Berg, Alexander P. Cole, Marieke J. Krimphove, et al. Comparative Effectiveness of Radical Prostatectomy Versus External Beam Radiation Therapy Plus Brachytherapy in Patients with High-risk Localized Prostate Cancer. <i>Eur Urol</i> 2019;75:552-5: Comparing Apples to Oranges: A Self-fulfilling Prophecy?. <i>European Urology</i> , 2019 , 75, e133-e134	10.2	
58	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019 , 5, 975-983	13.4	142
57	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 778-789	4	127
56	Key considerations when reviewing subsequent primary cancers following radiotherapy. <i>Lancet Oncology, The</i> , 2019 , 20, e291	21.7	0
55	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019 , 37, 599-610	2.8	6
54	Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial. <i>British Journal of Radiology</i> , 2019 , 92, 20181001	3.4	4
53	Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. <i>BMC Cancer</i> , 2019 , 19, 291	4.8	16
52	Phase 1 Trial of SBRT to the Prostate Fossa After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 50-60	4	8
51	Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. <i>JAMA Network Open</i> , 2019 , 2, e188006	10.4	122
50	F-fluciclovine PET-CT and Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. <i>Lancet Oncology, The</i> , 2019 , 20, 1286-1294	21.7	209
49	Androgen deprivation therapy in high risk prostate cancer.. <i>Translational Cancer Research</i> , 2019 , 8, 2216-2217	2.3	1
48	Reply to Marieke J. Krimphove, Junaid Nabi, Alexander P. Cole, and Quoc-Dien Trinh. Letter to the Editor re: Ronald D. Ennis, Liangyuan Hu, Shannon N. Ryemon, Joyce Lin, Madhu Mazumdar. Brachytherapy-based Radiotherapy and Radical Prostatectomy Are Associated with Similar Survival in High-risk Localized Prostate Cancer. <i>Clin Oncol</i> 2018;36:1492-8. Setting the Standard: The ACR Appropriateness Criteria. Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer. <i>Journal of the American College of Radiology</i> , 2019 , 16, S399-S416	6.7	1
47	ACR Appropriateness Criteria. Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer. <i>Journal of the American College of Radiology</i> , 2019 , 16, S399-S416	3.5	4
46	Optimal patient selection for stereotactic body radiotherapy. <i>Lancet Oncology, The</i> , 2019 , 20, e661	21.7	1
45	Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis. <i>JAMA Oncology</i> , 2019 , 5, 91-96	13.4	15
44	Treatment of the primary tumor in metastatic prostate cancer. <i>World Journal of Urology</i> , 2019 , 37, 2597-2606	7	

43	Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 896-905	27.4	171
42	Potential Impact of Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1714-1721	8.9	64
41	Hypo-fractionated stereotactic radiotherapy of five fractions with linear accelerator for vestibular schwannomas: A systematic review and meta-analysis. <i>Clinical Neurology and Neurosurgery</i> , 2018 , 166, 116-123	2	16
40	Comparison of lung tumor motion measured using a model-based 4DCT technique and a commercial protocol. <i>Practical Radiation Oncology</i> , 2018 , 8, e175-e183	2.8	2
39	Initial clinical observations of intra- and interfractional motion variation in MR-guided lung SBRT. <i>British Journal of Radiology</i> , 2018 , 91, 20170522	3.4	32
38	Discord Among Radiation Oncologists and Urologists in the Postoperative Management of High-Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 739-746 ²⁻⁷		4
37	Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 101, 883-888	4	6
36	Image-guided radiotherapy for prostate cancer. <i>Translational Andrology and Urology</i> , 2018 , 7, 308-320	2.3	23
35	Optimal Treatment for High-Risk Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 405	27.4	1
34	Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer. <i>European Urology Oncology</i> , 2018 , 1, 3-18	6.7	4
33	Magnetic Resonance Imaging Guidance Mitigates the Effects of Intrafraction Prostate Motion During Stereotactic Body Radiotherapy for Prostate Cancer. <i>Cureus</i> , 2018 , 10, e2442	1.2	5
32	MRI-guided Dose-escalated Salvage Radiotherapy for Bulky Bladder Neck Recurrence of Prostate Cancer. <i>Cureus</i> , 2018 , 10, e2360	1.2	0
31	Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 230-237	8.9	164
30	Reply to Thomas Van den Broeck, R. Jeffrey Karnes, and Steven Joniau's Letter to the Editor re: Amar U. Kishan, Talha Shaikh, Pin-Chieh Wang, et al. Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>Eur Urol</i> 2017;74:766-79; <i>European Urology</i> , 2017 , 72, e123-e124	10.2	0
29	Treatment trends for patients with brain metastases: Does practice reflect the data?. <i>Cancer</i> , 2017 , 123, 2274-2282	6.4	20
28	Standard fractionation external beam radiotherapy with and without intraoperative radiotherapy for locally recurrent rectal cancer: the role of local therapy in patients with a high competing risk of death from distant disease. <i>British Journal of Radiology</i> , 2017 , 90, 20170134	3.4	8
27	Prostate Cancer Antigen 3 Score Does Not Predict for Adverse Pathologic Features at Radical Prostatectomy or for Progression-free Survival in Clinically Localized, Intermediate- and High-risk Prostate Cancer. <i>Urology</i> , 2017 , 107, 171-177	1.6	3
26	External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 1045-1052	4	7

25	Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2017 , 27, 268-278	5.5	37
24	Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 516-525 ⁴		15
23	Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?. <i>Cancer</i> , 2017 , 123, 531-532 ⁴		2.4
22	Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy. <i>Brachytherapy</i> , 2017 , 16, 1106-1112	2.4	10
21	Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis. <i>European Urology</i> , 2017 , 71, 766-773	10.2	67
20	Online Adaptive Radiation Therapy: Implementation of a New Process of Care. <i>Cureus</i> , 2017 , 9, e1618	1.2	51
19	Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic. <i>Annals of Surgical Oncology</i> , 2016 , 23, 634-641	3.1	7
18	Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 946-955	4	7
17	Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data. <i>Therapeutic Advances in Medical Oncology</i> , 2016 , 8, 85-97	5.4	9
16	A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer. <i>Medical Dosimetry</i> , 2016 , 41, 87-91	1.3	29
15	SBRT and HDR brachytherapy produce lower PSA nadirs and different PSA decay patterns than conventionally fractionated IMRT in patients with low- or intermediate-risk prostate cancer. <i>Practical Radiation Oncology</i> , 2016 , 6, 268-275	2.8	22
14	Having Your Cake and Eating It Too: Combining SBRT and Multi-agent Chemotherapy in Locally Advanced Pancreatic Cancer. <i>Cureus</i> , 2016 , 8, e686	1.2	1
13	Anatomic and dosimetric changes in patients with head and neck cancer treated with an integrated MRI-tri-Co teletherapy device. <i>British Journal of Radiology</i> , 2016 , 89, 20160624	3.4	14
12	Radiation Therapy for Stage I Nonoperable or Medically Inoperable Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 716-726	3.9	5
11	Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer. <i>Practical Radiation Oncology</i> , 2015 , 5, 411-6	2.8	21
10	Pelvic nodal dosing with registration to the prostate: implications for high-risk prostate cancer patients receiving stereotactic body radiation therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 832-9	4	15
9	Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy. <i>British Journal of Radiology</i> , 2015 , 88, 20150658	3.4	5
8	Dosimetric feasibility of magnetic resonance imaging-guided tri-cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. <i>Practical Radiation Oncology</i> , 2015 , 5, 350-356	2.8	8

7	In Regard to Bauman et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 93, 1162-3	4	6
6	Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy. <i>Practical Radiation Oncology</i> , 2015 , 5, 330-337	2.8	25
5	Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma. <i>Practical Radiation Oncology</i> , 2015 , 5, 366-73	2.8	10
4	Correlation of Clinical and Dosimetric Parameters With Radiographic Lung Injury Following Stereotactic Body Radiotherapy. <i>Technology in Cancer Research and Treatment</i> , 2015 , 14, 411-8	2.7	8
3	Late rectal toxicity after low-dose-rate brachytherapy: incidence, predictors, and management of side effects. <i>Brachytherapy</i> , 2015 , 14, 148-59	2.4	19
2	Dose impact in radiographic lung injury following lung SBRT: Statistical analysis and geometric interpretation. <i>Medical Physics</i> , 2014 , 41, 031701	4.4	5
1	Quantification of gross tumour volume changes between simulation and first day of radiotherapy for patients with locally advanced malignancies of the lung and head/neck. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014 , 58, 618-24	1.7	8